Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

VEGF Levels in Aqueous, Vitreous and Subretinal Fluid in ROP Stage IV and V

This study has been completed.
Information provided by:
Asociación para Evitar la Ceguera en México Identifier:
First received: November 21, 2007
Last updated: November 23, 2007
Last verified: November 2007
To determine the degree of VEGF in Aqueous, vitreous and SRF in patients with ROP in stage V. Verifying that it is greater to that found in healthy newborn patients with different ocular pathology.

Condition Intervention Phase
Retinopathy of Prematurity
Procedure: Vitrectomy
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V

Resource links provided by NLM:

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • VEGF Levels [ Time Frame: one day ]

Enrollment: 16
Study Start Date: March 2007
Study Completion Date: June 2007
Intervention Details:
    Procedure: Vitrectomy
    Open-Sky vitrectomy, with resection of the tunica vasculosa lentis, and retinal reattachment
  Show Detailed Description


Ages Eligible for Study:   1 Month to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Premature newborns with less than 32 weeks of gestation.
  • Low birth weight (less than 1500gr)
  • Stage V ROP.
  • The parents has signed the informed consent.

Exclusion Criteria:

  • Previous treatment of ROP.
  • Surgery or another ocular pathology of any type.
  • Systemic diseases, including diabetes mellitus, congestive heart failure acute renal insufficiency, Chronic renal insufficiency, high blood pressure.
  • Lack of Informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00563121

Asociación para Evitar la Ceguera en Mexico
Mexico, DF, Mexico, 04030
Asociacion Para Evitar la Ceguera en Mexico. Hospital Luis Sanchez Bulnes
Mexico City, Mexico D. F., Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Principal Investigator: Raul Velez-Montoya, MD Asociación para Evitar la Ceguera en Mexico
Principal Investigator: Hugo Quiroz-Mercado, MD Asociación para Evitar la Ceguera en Mexico
  More Information

Publications: Identifier: NCT00563121     History of Changes
Other Study ID Numbers: ROP001
Study First Received: November 21, 2007
Last Updated: November 23, 2007

Keywords provided by Asociación para Evitar la Ceguera en México:
Retinopathy of Prematurity
Vascular Endothelial Growth Factor
Subretinal Fluid
VEGF levels in Aqueous, Vitreous and subretinal Fluid

Additional relevant MeSH terms:
Retinal Diseases
Premature Birth
Retinopathy of Prematurity
Eye Diseases
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Infant, Premature, Diseases
Infant, Newborn, Diseases
Endothelial Growth Factors
Growth Substances
Physiological Effects of Drugs processed this record on May 25, 2017